Stirlescent®
250mg naproxen effervescent tablets
Adverse events should be reported
Reporting forms and information can be found at yellowcard.mhra.gov.uk or downloaded from Google Play or the Apple App Store.
Adverse events should also be reported to JensonR+ on 01271 314 320 or Stirling Anglian Pharmaceuticals on 0345 527 0680.
Information for Healthcare Professionals
The licensed indication for Stirlescent® is for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in patients aged 18 years or over with a creatinine clearance of at least 30 ml/min. Contraindicated in patients with moderate or severe renal impairment.
Stirlescent® offers a lower cost option for treatment with naproxen in patients who may experience swallowing difficulties and who require a liquid form of NSAID.
Stirlescent® is used to treat adults only.
Stirlescent® is the only effervescent naproxen available in the UK.
